Drug Profile
Serabelisib - Takeda Oncology
Alternative Names: INK-1117; MLN-1117; PETRA-06; TAK-117Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Intellikine
- Developer Avera Cancer Institute; Baylor Research Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); Takeda; Takeda Oncology
- Class Antineoplastics; Imidazoles; Morpholines; Pyridines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometrial cancer; Renal cell carcinoma; Triple negative breast cancer
- No development reported Solid tumours
- Discontinued Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
Most Recent Events
- 01 Dec 2022 Baylor Research Institute and Takeda completes a phase II trial for Triple-negative-breast cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT03193853)
- 27 Sep 2022 No development reported - Phase-II for Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, Italy, Czech Republic, France, United Kingdom, Canada (PO)
- 22 Apr 2022 Faeth Therapeutics initiates a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT05300048)